What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective
Keyword(s):
Given China’s relatively weak innovative and regulatory capacity compared to developed countries, China’s progress on COVID-19 vaccines is especially impressive. We summarize three key lessons from China’s experience with COVID-19 vaccine R&D: i) set strategic vaccine R&D goals and achieve broad consensus; ii) strengthen coordination across government agencies; and iii) adopt the state-driven collaborative model.
Keyword(s):
2019 ◽
Vol 13
(1)
◽
pp. 5-36
Keyword(s):
Keyword(s):
2001 ◽
Vol 19
(4)
◽
pp. 43-63
◽
Keyword(s):
Keyword(s):
2020 ◽
Vol 93
(4)
◽
pp. 101-108